Emergent BioSolutions Inc. — Director's Dealing 2019

Feb 21, 2019

SEC Form 4/A — Form 4/A

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2018-11-19

Reporting Person: El-Hibri Fuad (Director, Chairman, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-19	Common Stock	M	20000	$14.44	Acquired	1508675	Direct
2018-11-20	Common Stock	M	15173	$14.44	Acquired	1503848	Direct
2018-11-26	Common Stock	M	25000	$13.38	Acquired	1513675	Direct
2018-11-27	Common Stock	M	20832	$13.38	Acquired	1509507	Direct
2018-11-27	Common Stock	S	20832	$69.59	Disposed	1488675	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-11-19	Employee Stock Options (Right to Buy)	$14.44	M	20000	Disposed	2019-03-12	Common Stock (20000)	Direct
2018-11-20	Employee Stock Options (Right to Buy)	$14.44	M	15173	Disposed	2019-03-12	Common Stock (15173)	Direct
2018-11-26	Employee Stock Options (Right to Buy)	$13.38	M	25000	Disposed	2020-03-11	Common Stock (25000)	Direct
2018-11-27	Employee Stock Options (Right to Buy)	$13.38	M	20832	Disposed	2020-03-11	Common Stock (20832)	Direct

Footnotes

F1: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2: The reported option exercises were inadvertently omitted from the original Form 4 filed with the Securities and Exchange Commission ("SEC") on November 21, 2018, which reported the sales of shares of the Issuer's common stock ("Common Stock") only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises.

F3: The number of shares of Common Stock directly beneficially owned by the Reporting Person reported on this amended Form 4 gives effect to the sales of Common Stock by the Reporting Person as reported on the Forms 4 filed with the SEC on November 21, 2018 and November 28, 2018, as applicable.

F4: The reported option exercises were inadvertently omitted from the original Form 4 filed with the SEC on November 28, 2018, which reported the sales of shares of Common Stock only, rather than the exercises of the options and subsequent sales of the shares of Common Stock acquired upon such exercises.

F5: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.31 to $70.32.

F6: The options vested in three equal installments on March 12, 2013, March 12, 2014 and March 12, 2015.

F7: The options vested in three equal installments on March 11, 2014, March 11, 2015 and March 11, 2016.